Most recent update: Thursday, November 22, 2018 - 07:44

Bariatric News - Cookies & privacy policy

You are here

Patent

ReShape Lifesciences gains Chinese Patent Gastric Vest System

The Chinese patent is directed to a novel laparoscopic gastric restriction device to treat obesity

ReShape Lifesciences has announced that The State Intellectual Property Office of The People's Republic of China has granted a device patent to the company that expands the patent portfolio for the ReShape Vest (Gastric Vest System (GVS). The Chinese patent number ZL201410538627.2, which is titled, ‘Gastric Restriction Devices for Treating Obesity’, is directed to a novel laparoscopic gastric restriction device to treat obesity.

''We are very excited about this patent that helps protect our proprietary, minimally invasive, novel technology to address the significant obesity market in China,'' said Dan Gladney, Chief Executive Officer and Chairman of the Board of ReShape Lifesciences. ''Obesity has become a major concern in China, where obesity-related co-morbidities such as hypertension, diabetes and coronary heart disease are costing the country significant dollars and where the government's recently-released ‘Healthy China 2030’ blueprint is driving public health as a priority.''

The GVS is an investigational, minimally invasive, laparoscopically implanted medical device being studied for weight loss in obese and morbidly obese patients. The device wraps around the stomach, emulating the effect of conventional weight-loss surgery, and enables gastric volume reduction without permanently changing patient anatomy. In a pilot study conducted outside the US, at 12 months, Vest patients demonstrated a mean percent excess weight loss (%EWL) of 85%, an average drop in HbA1c (Haemoglobin A1c) of 2.1 points, and an average waist circumference reduction of 38cms.

ReShape Lifesciences recently commenced site initiation training for the first clinical trial site that will participate in the multi-centre trial of the ReShape Vest to support CE Mark approval. The trial, which will include study centres in Spain, Germany, Belgium, The Netherlands and the Czech Republic, seeks to enrol up to 95 subjects who will be followed for two years. Primary endpoints in this trial include percent total body weight loss and adverse event rates at 12 months. Enrolment is expected to begin in the third quarter of 2018.

EnteroMedics recently acquired the Gastric Vest System through its acquisition of BarioSurg in May 2017.

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.